AID undertakes research on parasite, viral, bacterial and fungal infectious diseases, and brings together basic sciences, clinical research and technological expertise where both UQ and QIMR have strengths.
Other Research Areas
Diagnostics: The capacity to detect microbial pathogens in patients is the first step in the treatment of infectious disease treatment. We will use the full range of technological platforms available within AID to develop accurate and rapid diagnostic tests for the identification of viral, bacterial, fungal and parasitic pathogens.
Antimicrobial resistance: The rise of antimicrobial resistant pathogens is one of the major health challenges facing the human population. We will examine the capacity of mobile genetic elements to promote the spread of antimicrobial resistance. Tracking the spread of microbial resistance, and surveillance for the emergence of new resistance genes, will inform strategies for the control of multi-resistant pathogens in the health system.
Emerging infectious diseases: New infections continue to emerge as the result of environmental disruption and increased mobility of the human population. Recent examples include Hendra virus, dengue, Japanese encephalitis, Murray Valley encephalitis, West Nile like-virus, multi drug-resistant pathogens including tuberculosis, pathogenic E. coli and malaria as well as group A streptococci. We will combine expertise in classical and new-age diagnostic approaches to develop and apply the novel diagnostic methodologies for rapid detection of new emerging and re-emerging infections.
Host-pathogen interactions: The examination of the interaction between infectious disease agents and the human host is an area of significant expertise within AID. We will utilise this expertise in the examination of specific host-pathogen interactions, and extend this research to understand the role of the host immune system in the prevention or development of infectious diseases.
Vaccine development: AID researchers possess a strong translational record in the field of vaccinology, notably in the development of new vaccines, the development of the needle-less nanopatch vaccine delivery system and the formulation of novel adjuvants. We will utilise these technologies to develop new vaccines against a range of infectious disease agents.